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Inhibitory, GABAergic Nerve Terminals Decrease at 
Sites of Focal Epilepsy 
Abstract. Using an immunocytochemical method for the localization of the y­
aminobutyric acid (GABA) synthesizing enzyme, glutamic acid decarboxylase 
(GAD), we have observed GABAergic nerve terminals distributed throughout all lay­
ers of normal monkey sensorimotor cortex. These terminals displayed ultrastructural 
characteristics that suggested that they arose from aspinous and sparsely spinous 
stellate neurons. In monkeys (Macaca mulattaand M. fascicularis) made epileptic by
cortical application r�falumina gel, a highly significant numerical decrease of GAD­
positive nerve terminals occurred at sites o
f 
seizure foci indicating a functional loss 
of GABAergic inhibitory synapses. A loss of such inhibition at seizure foci could lead 
to epileptic activity of cortical pyramidal neurons. 
Epilepsy is a neurological disorder 
characterized by intermittent, general­
ized seizures involving motor and sen­
sory systems. Most epilepsies in humans 
are caused by tumors or by trauma to a 
brain region as a result of cranial in­
juries, including those produced by birtr 
canal obstructions (/). Human epilepsy 
has not been studied in as much detail as 
disorders in experimental animals pro­
duced by the application of various 
Macaca mulatta 
agents that initiate seizure activity; for 
example, alumina gel, cobalt, and pen­
icillin (2). Since these experimentally 
produced epileptic foci develop repro­
ducibly they have provided models for 
the study of human focal epilepsy. 
Several factors, including glial hyper­
trophy, ischemia, and increased concen­
trations of acetylcholine, have been sug­
gested as being involved in the onset of 
seizures (3). Another such factor, and 
one that is the concern of this report, in­
volves the inhibitory neurotransmitter y­
aminobutyric acid (GABA). It has been 
suggested that a reduction of this inhib­
itory substance could be responsible for 
seizure activity because results from bio­
chemical studies have shown decreases 
in both GABA (4) and its synthesizing 
enzyme, glutamic acid decarboxylase 
(GAD) (5), at seizure foci. 
In a recent immunocytochemical 
study, GAD has been localized within 
the axon terminals of aspinous and sparse­
ly spinous stellate neurons in the rat 
cerebral cortex (6). Since GAD has been 
found in a number of other brain regions 
within neurons that have been identified 
as GABAergic (7), it is probable that the 
presence of GAD is indicative of neurons 
that use GABA as a neurotransmitter. 
Therefore, the localization of GAD with­
in aspinous and sparsely spinous stellate 
neurons, together with evidence from 
physiological and pharmacological stud­
ies (8), strongly suggests that these neu­
rons are responsible for GABA-mediated 
inhibition in the cerebral cortex. Since 
these neurons are found in every cortical 
layer and project numerous axon termi­
nals to pyramidal cell somata, they could 
exert a powerful inhibitory effect on cor­
tical projection neurons. Furthermore, a 
decrease in the number of these inhib­
itory axon terminals could lead to sei­
zure activity of pyramidal neurons. To 
test this possibility, we compared the 
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Fig. 1. An ECG recording that was made just prior to fixation of the brain by intra vascular perfusion shows an alumina-induced epileptic focus in 
M. mulatta located around lead 5 as indicated by spike phase reversals in traces 3 to 5 and 5 to 7. 
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these analyses indicate a highly signifi­
cant decrease in the number of GABA­
ergic axon terminals at sites of seizure 
foci. 
The decreased number of GAD-posi­
tive terminals in our immunocytochemi­
cal preparations of epileptic monkey cor­
tex could be explained by an alumina gel­
produced loss of antigenicity of GAD 
molecules. However, this is unlikely 
since most of the alumina is located in 
macrophages with slight amounts in as­
trocytes (/6). Furthermore, not all of the 
GAD-positive terminals are lost at seiz­
ure foci, and the staining of the remain­
ing terminals indicates that the antigenic­
ity of GAD is not affected by the alumina 
gel. In addition, a differential loss of anti­
genicity caused by differences in the dif­
fusion of alumina from the application 
site is unlikely since, in monkeys with 
subarachnoid injections, the deep cortic­
al layers display similar decreases of 
GAD-positive terminals to those ob­
served in the superficial layers directly 
subjacent to the alumina gel. Therefore, 
the loss of immunocytochemically de­
tectable GAD from cortical axon termi­
nals indicates an actual loss of GAD 
molecules and this could be due either to 
a severe impairment of GAD synthesis, 
or to the degeneration of GABAergic so­
mata or their axon terminals, or both. 
central nervous system (18). Thus, our 
results in combination with those of the 
other studies cited in this report sup­
port a hypothesis that a loss of func­
tional GABAergic neurons leads to focal 
epilepsy. 
CHARLES E. RIBAK* 
Division of N eurosciences, 
City c?f Hope National Medical Center, 
Duarte, Cal(fornia 91010 
A. BASIL HARRIS 
Department of Neurological Surgery, 
University of Washington, Seattle 98195 
JAMES E. VAUGHN 
EUGENE ROBERTS 
Division of Neurosciences, 
City of Hope National Medical Center 
References and Notes 
I. A. J. Lewis, Mechanisms o
f 
Neurological Dis­
ease (Little Brown, Boston, 1976), pp. 329-342. 
2. D. A. Prince and K. J. Futamachi, Brain Res. 
11, 681 (1968); A. A. Ward, Jr., Electroencepha­
log. Clin. Neurophysiol. (Suppl.) 31, 75 (1972). 
3. H. D. Lux, Epilepsia 15,375 (1974); G. G. Som­
jen, Annu. Rev. Physiol. 37, 163 (1975); A. A.
Ward, Jr., in Dynamic Properties of Glial Cells, 
E. Schoffeniels et al., Eds. (Pergamon, Oxford,
1978), pp. 413-427; D. B. Tower, in Basic 
Mechanisms of the Epilepsies, H. H. Jasper, 
A. A. Ward, A. Pope, Eds. (Little Brown, 
Boston, 1%9), pp. 611-638; A. M. Goldberg, 
J. J. Pollock, E. R. Hartman, C. R. Craig, 
Neuropharmacology 11, 253 (1972). 
4. N. M. Van Gelder, A. L. Sherwin, T. Rasmus­
sen, Brain Res. 40,385 (1972); N. M. Van Geld­
er and A. Courtois, ibid. 43, 477 (1972). 
5. P. C. Emson and M. H. Joseph, ibid. 93, 91 
(1975). 
6. C. E. Ribak, J. Neurocytol. 7, 461 (1978). 
7. B. J. McLaughlin, J. G. Wood, K. Saito, R. Bar­
ber, J.E. Vaughn, E. Roberts, J.-Y. Wu, Brain 
Res. 76, 377 (1974); B. J. McLaughlin, R. Bar­
ber, K. Saito, E. Roberts, J.-Y. Wu, J. Comp. 
Neurol. 164, 305 (1975); C. E. Ribak, J. E.
Vaughn, K. Saito, R. Barber, E. Roberts,Brain 
Res. 116, 287 (1976); C. E. Ribak, J.E. Vaughn, 
K. Saito, ibid. 140, 315 (1978). 
8. K. Krnjevic, Physiol. Rev. 54,418 (1974); A. M.
Sillito, J. Physiol. (London) 250, 287 (1975);
D. R. Curtis and D. Felix, Brain Res. 34, 301 
(1971); E. Wallingford, R. Ostdahl, P. Zarzecki, 
P. Kaufman, G. Somjen, Nature (London) New 
Biol. 242, 210 (1973). 
9. A. B. Harris, Exp. Neurol. 49, 691 (1975). 
10. ---, Arch. Neurol. 26, 434 (1972). 
l I. Fixative solutions contained 4 percent para­
formaldehyde, 0.1 percent glutaraldehyde, and 
0.002 percent CaCl2 in a 0.12M phosphate buf­
fer. Specimens for light microscopy were infil­
trated with 30 percent sucrose solution, quickly 
frozen with Dry Ice, embedded in O.C.T. (Lab­
Tek Products), and cut on a cryostat at a thick­
ness of approximately 30 µ,m. Specimens for 
electron microscopy were sectioned on a Sorvall 
TC-2 tissue sectioner at a thickness of 150 µ,m 
and were rinsed in buffer overnight before being 
incubated in GAD immunochemical reagents. 
Sections were consecutively incubated for I 
hour in the following solutions; normal rat ser­
um, rabbit antiserum to GAD or control rabbit 
serum, goat antiserum to rabbit immunoglob­
ulin G. peroxidase-antiperoxidase Fab com­
plex, and 3,3'-diaminobenzidine in 4N HCI (Sig­
ma) and 0.006 percent H202 • Sections were 
rinsed in buffer for 2.5 hours after each in­
cubation. Sections were further processed for 
light and electron microscopic observations by 
established procedures. For more details, see R. 
P. Barber, J. E. Vaughn, K. Saito, B. J. 
McLaughlin, E. Roberts, Brain Res. 141, 35 
(1978); and (6) and (7). 
12. A. B. Harris and J. S. Lockard, Soc. Neurosci. 
Abstr. 3, 140 (1977); Ann. Neurol., in press. 
13. S. LeVay, J. Comp. Neurol. 150, 53 (1973); J. 
G. Parnavelas, K. Sullivan, A. R. Lieberman, 
K. E. Webster, Cell Tissue Res. 183,499 (1977); 
P. Somogyi, Brain Res. 136, 345 (1977); A. Pe­
ters and A. Fairen, J. Comp. Neurol. 181, 129 
(1978). 
14. E. G. Jones and S. P. Wise, J. Comp. Neurol. 
175, 391 (1977). 
15. B. J. Winer, Statistical Principles in Experimen­
tal Design (McGraw-Hill, New York, 1962). 
16. A. B. Harris, Exp. Neurol. 38, 33 (1973).
17. J. Fischer, Physiol. Bohemoslav. 18,387 (1969);
W. J. Brown, .in Epilepsy, Its Phenomena in
Man, M. A. B. Brazier, Ed. (Academic Press,
New York, 1973), pp. 337-374.
18. B. S. Meldrum, Int. Rev. Neurobiol. 17, I 
(1975): J. D. Wood, Prog. Neurobiol. 5, 77
(1975); D. B. Tower, in GABA in Nervous Sys­
tem Function, E. Roberts, T. N. Chase, D. B.
Tower, Eds. (Raven, New York, 1976), pp. 461-
478; B. S. Meldrum, Lancet 1978-ll, 304 (1978); 
P. C. Emson, J. Neurochem. 27, 1489 (1976). 
19. Supported by PHS grants, NS 12116, NS 01615, 
NS 04053, and NS 09037. We thank K. Saito, J.­
Y. Wu, and P. Salvaterra for providing the im­
munochemical reagents, C. Wimer for assist­
ance with the statistical analyses, L. Anderson, 
M. Nakashima, C. Vaughn, and J. R. Slemmon 
for technical assistance, and D. Dreier and R. 
Jin for secretarial assistance. A.B.H. is affiliated 
with the Child Development and Mental Retar­
dation Center, University of Washington, Se­
attle 98195. 
* Present address: Department of Anatomy, Uni­
versity of California, Irvine 92717. 
22 September 1978; revised 26 December 1978 
Although previous biochemical data 
have indicated decreased GAD activities 
at seizure foci (5), our results extend this 
finding and show a numerical decrease of 
GAD-containing axon terminals. Wheth­
er these terminals actually degenerate or 
merely lose immunocytochemically de­
tectable GAD is not known. However, a 
degeneration of GAD-containing termi­
nals is suggested by the results of ultra­
structural studies that show a decreased 
number of presumed inhibitory, symmet­
ric synaptic junctions with somata and 
dendritic shafts of cortical neurons at 
seizure foci (/7). In either event, a func­
tional loss of GABAergic cortical neu­
rons would occur. Our experimental 
preparations indicate that the magnitude 
of this loss is significant and could be ex­
pected to reduce the inhibitory synaptic 
control of pyramidal neurons, thus lead­
ing to a hypersensitivity of these cells to 
normal excitatory synaptic inputs (4, 5). 
The reason for this loss of GABAergic 
terminals at seizure foci is unknown, but 
it is possible that aspinous stellate neu­
rons may be highly susceptible to altera­
tions induced by alumina treatments. 
Further support for a GABAergic in­
volvement in epilepsy is derived from 
pharmacological studies that show that 
certain convulsant and anticonvulsant 
drugs act at GABAergic synapses in the 
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